UBS lowered the firm’s price target on Arrowhead (ARWR) to $63 from $71 and keeps a Buy rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals: Strong Financial Position with Pipeline Uncertainties Justifying Hold Rating
- Arrowhead Pharmaceuticals: Hold Rating Amid Promising Developments and Regulatory Uncertainties
- Arrowhead price target lowered to $17 from $21 at Citi
- Hold Rating for Arrowhead Pharmaceuticals Amid Revenue Gains and Market Uncertainties
- Arrowhead Pharmaceuticals Reports Strong Q2 2025 Results